Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
ApexOnco Front Page
Recent articles
What similarly acting projects are still unpartnered?
Data on the group’s lead project, the PD-1 x CTLA-4 bispecific vudalimab, are far from emphatic.
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
An “optimised formulation” of bezuclastinib looks promising, but the safety question remains open.
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
